Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics develops gene therapies that aim to treat inherited heart diseases in patients with genetic cardiomyopathies. It last closed at $2.85 on Nov 17, down 11.61% on the day. LXEO reports earnings on Mon, Dec 14, 2026. The average 12-month price target from 2 analysts is $26.00 (+810.7% from the last close), with a high of $37.00 and a low of $15.00.
Key Stats
Last 12 monthsNot reported for this period.
From LXEO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 2 analysts who set a price target on LXEO in the past 90 days. The average target is $26.00, with a high of $37.00 and a low of $15.00, compared with the last close of $2.85.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 16 | Cantor Fitzgerald | Target raised | Buy | $23 → $37 |
| Nov 12 | Cantor Fitzgerald | Reiterated | Buy | $23 |
| Sep 23 | Leerink Partners | Maintained | Buy | $15 |
| Jun 25 | JP Morgan | Maintained | Buy | $9 |
Technical Analysis
The stock is 5% below its 20 day and 16% below its 50 day average. It is 73% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 44). The nearest support is the swing low (Nov 6) at $2.70, and the nearest resistance the 20 day average at $3.00.
| RSI (14) | 44.05 | Middle of its range | Neutral |
| MACD | -0.08 | Above its signal line | Bullish |
| Stochastic | 23.7 | Middle of its range | Neutral |
| ADX (14) | 19.6 | No clear trend | |
| Williams %R | -90.3 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | 1.4 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −8.2% | Change over 10 sessions | Bearish |
| ATR (14) | $0.38 | Typical daily range, 13.1% of price |
| RSI (14) | 33.19 | Weak, oversold below 30 | Neutral |
| MACD | -0.73 | Below its signal line | Bearish |
| Stochastic | 11.3 | Near the bottom of its range | Oversold |
| ADX (14) | 24.1 | Weak trend | |
| Williams %R | -89.3 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -58.2 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −32.8% | Change over 10 sessions | Bearish |
| ATR (14) | $0.76 | Typical daily range, 26.8% of price |
What happened before
See how LXEO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How LXEO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.
Whale Options Flow
90DNo whale options trades in LXEO in the last 90 days.
LXEO Institutional Ownership
Full report →- ▲80 buying vs 55 selling
- ▲Held by funds +2.6 pts
- ▲Funds holding +11
- ▲Superinvestors: 4 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 153 | 142 | +7.7% |
| In funds' top 10 | 1 | 1 | 0.0% |
| Held by funds | 110.7% | 108.2% | +2.6 pts |
| New / increased | 30 / 50 | 27 / 58 | −5.9% |
| Reduced / sold out | 37 / 18 | 39 / 23 | −11.3% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LXEO is in one of them and how their past LXEO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered LXEO in an article yet. Here's the latest on the wider market.
About Lexeo Therapeutics
Lexeo Therapeutics is a biotechnology company based in New York that develops gene therapies for inherited heart diseases. Its candidates are designed to deliver working copies of disease-linked genes to heart muscle cells. The lead programs target Friedreich ataxia cardiomyopathy and arrhythmogenic cardiomyopathy caused by PKP2 gene mutations, and the company is also developing candidates for other genetic heart conditions. Its target patients have genetic heart diseases with few or no approved treatments.
- Headquarters
- New York, NY



